Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice.

[1]  W. Oyen,et al.  Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention , 2010, Journal of Nuclear Medicine.

[2]  R. Valkema,et al.  Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  E. Krenning,et al.  Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. , 2010, Seminars in nuclear medicine.

[4]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Giovanni Paganelli,et al.  Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Eva Forssell-Aronsson,et al.  Effects of Treatment with 177Lu-DOTA-Tyr3-Octreotate on Uptake of Subsequent Injection in Carcinoid-Bearing Nude Mice , 2007 .

[7]  B. Bernard,et al.  Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences. , 2007, Nuclear medicine and biology.

[8]  F. Forrer,et al.  Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  S. Herget-Rosenthal,et al.  How to estimate GFR-serum creatinine, serum cystatin C or equations? , 2007, Clinical biochemistry.

[10]  T. Visser,et al.  Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  T. de Baère,et al.  A Phase II Study of Irinotecan with 5-Fluorouracil and Leucovorin in Patients with Pretreated Gastroenteropancreatic Well-Differentiated Endocrine Carcinomas , 2006, Oncology.

[12]  W. Oyen,et al.  Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  W. Oyen,et al.  Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  Eva Forssell-Aronsson,et al.  Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour , 2005, British Journal of Cancer.

[15]  T. Visser,et al.  Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  S. Lipsitz,et al.  Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Visser,et al.  Localisation and mechanism of renal retention of radiolabelled somatostatin analogues , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Douglas B. Evans,et al.  Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Dale,et al.  Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. , 2004, Cancer biotherapy & radiopharmaceuticals.

[20]  H. V. van Boven,et al.  Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  E. Christensen,et al.  Protein reabsorption in renal proximal tubule—function and dysfunction in kidney pathophysiology , 2004, Pediatric Nephrology.

[22]  A. Peters,et al.  Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. , 1993, British Journal of Cancer.

[23]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[24]  Raffaella Barone,et al.  Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  L. T. Dillman,et al.  MIRD : radionuclide data and decay schemes , 1989 .